BI
ESPR

BVF Inc’s Esperion Therapeutics ESPR Stock Holding History

BVF Inc’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-712,770
Closed -$8.92M – 31
2016
Q4 		$8.92M Buy
712,770
+218,898
+44% +$2.61M 1.79% 17
2016
Q3 		$6.84M Sell
493,872
-5,270
-1% -$59.7K 1.29% 21
2016
Q2 		$4.93M Sell
499,142
-107,659
-18% -$1.78M 1.05% 24
2016
Q1 		$10.3M Buy
+606,801
New +$9.76M 2.54% 16

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc's ESPR Position: Q1 2017 in Review

BVF Inc sold out of Esperion Therapeutics (ESPR) in Q1 2017, closing a stake of 712,770 shares — an estimated $8.92M sold.

BVF Inc first reported a position in ESPR in Q1 2016 and held it in 4 quarters. The position peaked at $10.3M in Q1 2016. 119 funds tracked by Wall St. Rank hold ESPR as of Q1 2017.

  • BVF Inc reported no remaining Esperion Therapeutics position as of Q1 2017 after selling out during the quarter.
  • BVF Inc sold 712,770 Esperion Therapeutics shares in Q1 2017, an estimated $8.92M.
  • BVF Inc first reported a position in Esperion Therapeutics in Q1 2016 and held it in 4 quarters.
  • BVF Inc's Esperion Therapeutics position peaked at $10.3M in Q1 2016.
  • 119 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2017.

Based on BVF Inc's 13F filing for Q1 2017, filed 15 May 2017.